Non-coding SNPs in the protein tyrosine phosphatase non-receptor type 2 (PTPN2) locus have been linked with several autoimmune diseases, including rheumatoid arthritis, type I diabetes, and inflammatory bowel disease. However, the functional consequences of these SNPs are poorly characterized. Herein, we show in blood cells that SNPs in the PTPN2 locus are highly correlated with DNA methylation levels at four CpG sites downstream of PTPN2 and expression levels of the long non-coding RNA (lncRNA) LINC01882 downstream of these CpG sites. We observed that LINC01882 is mainly expressed in T cells and that anti-CD3/CD28 activated naïve CD4 þ T cells downregulate the expression of LINC01882. RNA sequencing analysis of LINC01882 knockdown in Jurkat T cells, using a combination of antisense oligonucleotides and RNA interference, revealed the upregulation of the transcription factor ZEB1 and kinase MAP2K4, both involved in IL-2 regulation. Overall, our data suggests the involvement of LINC01882 in T cell activation and hints towards an auxiliary role of these non-coding SNPs in autoimmunity associated with the PTPN2 locus.
Deregulation of immune response is a hallmark of autoimmune diseases, which likely involves multiple immune mechanisms. T cell-related regulation is often considered to be important for autoimmune diseases, although it is hard to distinguish causality in a sequence of T and B cell-related immunological events during the course of disease development. Genetic association studies inform about possible causal germ line variations that regulate cellular phenotypes and could precede development of clinical symptoms. Therefore, the study of functional consequences of diseaseassociated genetic variants is important for understanding disease mechanisms and for discovering new drug targets. However, the annotation of signals to the closest gene in genome-wide association (GWA) studies has often been proven inaccurate and sometimes even misleading [1e4] . It requires broad assessment of the function of genes sometimes relatively distant from the association hit. This is in part due to linkage disequilibrium between genetic markers, but is also due to complex relation between genomic sequences and chromatin structure.
Several diseases associate with genetic variations at the locus where the protein tyrosine phosphatase 2 (PTPN2) is located, including type 1 diabetes (T1D) [5] , juvenile idiopathic arthritis (JIA) [6] , inflammatory bowel disease (IBD) [7] , and rheumatoid arthritis (RA) [8] . PTPN2 has been shown to act on several phosphorylated proteins to regulate cytokine signaling [9] . The most strongly associated SNPs in the PTPN2 locus in RA are the intronic SNPs rs2542151, rs1893217, rs62097857, rs7234029, and rs8083786 [8,10e15] . In addition, the intronic SNPs rs657555 and rs2847297 were associated with RA in a Korean and Japanese population, respectively [16, 17] . Even though multiple SNPs within the PTPN2 locus have been discovered, the functional consequences of these variations in the pathogenesis of RA remain unclear.
The majority of associated variants identified by GWA studies lie within non-coding regions [18] . Various studies have shown that genetic variations within non-coding regions may cause different consequences for regulating genes. Intronic variations might be affecting alternative splicing, chromatin modifications, gene expression, and DNA methylation levels [2, 19, 20] . Also in many cases, the associated SNPs seem to act through the disruption of transcription factor binding sites [21] .
In this study, we investigated the autoimmune disease associated PTPN2 locus. Our results show that SNPs in the PTPN2 locus are associated with changes in levels of DNA methylation at four CpG sites 7.5 kb downstream of PTPN2 and changes in expression of the long non-coding RNA (lncRNA) LINC01882. Further, silencing of this lncRNA suggested a transcription regulation pathway in T cells that could be involved in RA and other autoimmune diseases where PTPN2 SNPs are known to be associated, thus providing a functional link between GWA hits and disease.
Materials and methods

Study approval
This study was performed with ethical approval from the local Ethical Boards according to the Swedish law and informed consent was received from participants included in the study. All RA cases met the American College of Rheumatology 1987 criteria for RA [22] .
DNA methylation
Methylation data for whole blood genomic DNA was obtained from our previous study (GSE42861) [23] . In short, bisulphite converted DNA from whole blood from 335 healthy controls and 354 ACPA-positive RA patients were analyzed using the Illumina HumanMethylation450 BeadChip Array. These samples were genotyped with the Illumina HumanHap300 Array [24] . SNP imputation was done with the 1000G project data as a reference. Only SNPs with !95% posterior probability, MAF !0.01, missing rate 0.05 and HWE P-value ! .001 were used for the analyses. 417 normalized CpG sites 1 Mb up-and downstream of the PTPN2 gene (11,785,478e13,929,643 bp, GRCh38) were tested for association with 37 SNPs (peak signals (rs1893217, rs11875687, rs62097857, rs2847293, rs12971201, rs8083786, and rs2542151) and SNPs in high LD; r 2 > 0.8) from the PTPN2 locus. The R package GEM (release 3.5) [25] was used to identify methQTLs using the covariates gender, age, and smoking status.
eQTL
Expression data for PBMCs was obtained from our previous COMBINE study [26] . In short, RNA of three patient groups and healthy individuals was purified using isopropanol extraction and sequenced using the TruSeq RNA sample preparation kit (2 Â 100 bp) on an Illumina HiSeq 2000 sequencer (Aros Applied Biotechnology center). After quality filtering of reads and adaptor removal, TopHat2 (version 2.0.10) was used to align reads to the hg19 assembly. Gene expression was quantified using HTSeq followed by TMM-normalization, mean-scaling and log2 transformation. Genotyping was performed using the HumanOmniExpress BeadChip Kit and Illumina OmniExpress arrays (12v1). A linear mixed model (nlme package (version 3.1e13.1)) was used to calculate the associations of SNPs and gene expression levels, with gender (and patient groups) as a fixed effect and study individuals as a random effect.
Gene-gene interactions
Gene-gene interactions were assessed by testing for additive interactions (departure from additivity) using the GEIRA algorithm (http://www.epinet.se) [27] in R (version 3.2.0). SNPs in PTPN2 locus (including 5 kb flanking regions (12790478e12889338 bp, GRCh38)) were extracted from EIRA [24] and NARAC GWA data [28] . Interactions were investigated by calculating the attributable proportion (AP) due to interaction with 95% confidence interval (95% CI) between 11 SNPS in the PTPN2 region and HLA-DRB1 SE using a dominant genetic model [27] .
Sorting of PBMCs
PBMCs from healthy individuals (Uppsala Biobank) were isolated on a Ficoll gradient (GE Healthcare). CD4þ T cells, CD8þ T cells, CD14þ monocytes, and CD19þ B cells were isolated using magnetic beads on the autoMACS Pro Separator (Miltenyi Biotec). RNA was extracted using the RNeasy Mini kit (Qiagen). Sequencing libraries were prepared using the Illumina TruSeq stranded total RNA sample preparation kit with ribosomal depletion using RiboZero (2 Â 125 bp) and analyzed on an Illumina HiSeq 2500 sequencer (SNP&SEQ Technology Platform, Uppsala, Sweden). At least 20 million reads were produced per sample. Pre-filtering on quality of reads using cutadapt (version 1.9.1) was applied (-q 30 -a AGATCGGAAGAGCA-CACGTCTGAACTCCAGTCAC -A AGATCGGAAGA-GCGTCGTGTAGG-GAAAGAGTGTAGATCTCGGTGGTCGCCGTATCATT -m 40). Filtered reads were aligned to the hg38 assembly and quantified using STAR (version 2.5.1b) [29] with default settings, followed by TMMnormalization, mean-scaling and log2 transformation.
Activation of naïve CD4
þ T cells
Expression data for naïve CD4 þ T cells and CD3/CD28 activated naïve CD4 þ T cells was obtained from GSE94859. In short, naïve
, CD45RAþ, CCR7þ) were sorted from PBMCs of healthy individuals using an influx sorter (BD) and activated using anti-CD3/CD28 beads (Dynabeads) for 16 h. RNA was extracted using the RNeasy Mini kit (Qiagen). Sequencing libraries were prepared using the Illumina TruSeq mRNA kit (poly(A) selection) on the Illumina HiSeq 2500 (SciLifeLab NGI Stockholm, Sweden). Reads were aligned against the hg38 genome using STAR and quantified using rpkmforgenes.py (version 13 March 2015).
Knockdown of LINC01882
Jurkat cells (LGC Standards) were kept in RPMI-1640 medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum (Sigma-Aldrich), L-glutamine (Gibco) and penicillin/streptomycin (Gibco) in a 37 C incubator with 5% CO 2 . Jurkat cells were transfected with a mixture (50 nM) of a dsiRNA (Integrated DNA Technologies) and an antisense LNA™ GapmeR (Exiqon) targeting LINC01882 using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. The following target sequences were used: dsiRNA (5 0 -AAATAAAGGATTCTAGTTATGTGAA-3 0 ) and antisense LNA™ GapmeR (5 0 -ACTGATCTGAGGAGAA-3 0 ). A mixture of the dsiRNA NC1 and the antisense LNA™ GapmeR (5 0 -AACACGTC-TATACGC-3 0 ) was used as negative control. Cells were harvested 24 and 48 h after transfection. Total RNA was extracted with the RNeasy Mini kit (Qiagen) according to manufacturer's instructions. Samples were treated with DNase (Qiagen) for 20 min at room temperature to avoid contamination with genomic DNA. RNA was converted into cDNA using the iScript cDNA Synthesis Kit (Bio-Rad). Efficiency of knockdown was evaluated by qPCR.
Quantitative real-time PCR
qPCR quantification was carried out using iQ SYBR Green Supermix (Bio-Rad) and primers detecting LINC01882 (forward primer 5 0 -GTGCACCACTGTGTGTCTCC-3 0 and reverse primer 5 0 -GATGAGTCCTCGGGAATGAG-3 0 ) and PTPN2 (forward primer 5 0 -GCATTGTGGAGAAAGAATCGGTTA-3 0 and reverse primer 5 0 -TCTGACAAGAGCTTCACACTGA-3 0 ) on a BioRad CFX384 Real-Time PCR Detection System with the following protocol: 95 C for 3 min, followed by 40 cycles of 95 C for 10 s and 57 C for 30 min. The endogenous controls SFRS9 (forward primer 5 0 -TGTGCA-GAAGGATGGAGT-3 0 and reverse primer 5 0 -CTGGTGCTTCTCTCAG-GATA-3 0 ) and HPRT (forward primer 5 0 -TGACACTGGCAAAAC-AATGCA-3 0 and reverse primer 5 0 -GGTCCTTTTCACCAGCAAGCT-3 0 ) were used. Data was analyzed with the SDS 2.4 software of Applied Biosystems before applying the DDCt method [30] .
RNA sequencing
The quality of each RNA sample was characterized using a RNA 6000 Nano Chip (Agilent Technologies) on the Agilent Bioanalyzer 2100. RNA (RIN value above 8) was fragmented and prepared into sequencing libraries using the Illumina TruSeq stranded total RNA sample preparation kit with ribosomal depletion using RiboZero (2 Â 125 bp) and analyzed on an Illumina HiSeq 2500 sequencer (SNP&SEQ Technology Platform, Uppsala, Sweden). On average, 50 million reads were produced per sample. Pre-filtering on quality of reads using cutadapt (version 1.9.1) was applied (-q 30 -a AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC -A AGATCGGAAGA-GCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGGTCGCCGTATCATT -m 40). Filtered reads were aligned to the hg38 assembly and quantified using STAR (version 2.5.1b) [29] with default settings. For lncRNAs, the reads were aligned to the FANTOM CAT assembly [31] and quantified using STAR. Differentially expressed genes were identified using DESeq2 (version 1.16.1).
In silico analyses
methQTL data was obtained from the mQTL database [32] . eQTL data was obtained from the following eQTL databases: Geuvadis Data Browser (http://ebi.ac.uk/Tools/geuvadis-das/) [33] , eQTL Browser (http://eqtl.uchicago.edu/), GTEx Portal (http://gtexportal. org/) [34] , and NCBI eQTL Browser (www.ncbi.nlm.nih.gov/ projects/gap/eqtl/index.cgi). Potential consequences of the PTPN2 variants were predicted using the online data sources HaploReg v4.1 (http://www.broadinstitute.org/mammals/haploreg/haploreg. php) [35] and RegulomeDB (www.regulomedb.org) [36] .
Statistics
Statistical tests were performed using R (version 3.3). A linear regression model (GEM package in R, release 3.5) was used for methQTLs and a linear mixed model (nlme package in R, version 3.1e13.1) was used for eQTLs. The nonparametric Wilcoxon signedrank test was used to determine the expression levels between naïve CD4 þ T cells before and after CD3/CD28 activation. Values were considered to be significantly different when P-value < .05.
Results
SNPs in the PTPN2 locus are associated with differential methylation at four CpG sites downstream of PTPN2
Previous GWA studies have shown that several noncoding SNPs in the PTPN2 locus are associated with T1D, IBD, JIA, and RA. In order to determine if such PTPN2 risk variants affect the epigenetic profile, we investigated 37 SNPs (the peak signals and SNPs in high LD; r 2 > 0.8) for their association with the level of DNA methylation at 417 CpG sites located in a 2 Mb window around the PTPN2 locus. Analyses were performed based on the DNA methylation data in whole blood samples of 335 healthy individuals from the EIRA study measured by the Illumina HumanMethylation450 BeadChip Array [23] . We detected a strong association for most of the SNPs and DNA methylation levels at four of the CpG sites. The CpG sites included cg23598886, cg23544223, cg24737193, and cg09945482 and are located in a CpG island 7.5 kb downstream of PTPN2. A highly significant association was found for the SNP rs1893217 and the four CpG sites (Fig. 1A ) (cg23598886 (P ¼ 2.73 Â 10
À30
), cg23544223 (P ¼ 6.99 Â 10 À29 ), cg09945482 (P ¼ 9.43 Â 10 À17 ), and cg24737193 (P ¼ 1.14 Â 10 À16 )). The SNPs rs2847293 (in high LD with rs1893217), rs11875687, and rs8083786 (in high LD with rs11875687) are also highly associated with cg23598886 (Fig. 1B) and the other three CpG sites. Carriers of the minor allele (G allele) of rs1893217, which is associated with RA, showed lower methylation levels at the CpG sites in the CpG island (Fig. 1C) . By interrogating the mQTL database [32] , variable levels of methylation for the four CpG sites in relation to SNPs in the PTPN2 locus were confirmed (data not shown). These results show that autoimmune disease associated non-coding SNPs in the PTPN2 locus are correlated to differential methylation at four CpG sites in healthy individuals.
SNPs in the PTPN2 locus are associated with the expression of lncRNAs
Given the identified relationship between SNPs in the PTPN2 locus and the levels of DNA methylation at four CpG sites 7.5 kb downstream of PTPN2, we tested the relation of 58 SNPs (the peak signals and SNPs in high LD; r 2 > 0.8) to the level of expression of genes around PTPN2 (cis-eQTL). Interrogating the GTEx database [34] , we found that SNPs in the PTPN2 locus are only weakly associated with the expression of PTPN2 in whole blood ( Fig. 2A) . However, highly significant associations were found for SNPs in the PTPN2 locus and expression of the lncRNAs LINC01882 (Fig. 2B) and RP11-973H7.1 (Fig. 2C) in whole blood, which are located about 28 kb and 1.5 kb, respectively, downstream of the CpG island. The most significant association was found for the SNP rs2847291 (in high LD with rs12971201). Carriers of the minor allele of rs2847291 showed lower expression levels of LINC01882 (P ¼ 6.37 Â 10 À14 ) and
To confirm these results, we tested the association of SNPs from the PTPN2 locus and the expression of PTPN2 and the lncRNAs LINC01882 and RP11-973H7.1 in peripheral blood mononuclear cells (PBMCs) of 59 healthy individuals from the COMBINE study [26] . We found that the SNPs are not associated with the expression of PTPN2 (Fig. 2D ), but weak associations with LINC01882 (Fig. 2E) and RP11-973H7.1 (Fig. 2F) were detected, thus replicating the data from the GTEx database. The SNP rs2847291 is also associated with the expression of RP11-973H7.1 (P ¼ 7.95 Â 10 À3 ) and LINC01882
(P ¼ 2.94 Â 10 À2 ) in PBMCs. The most significant association was found for the SNP rs2847281 (also in high LD with rs12971201) and the expression of RP11-973H7.1 (P ¼ 1.95 Â 10
À3
). The SNP that is most significantly associated with the expression of LINC01882 is rs11875687 (P ¼ 7.99 Â 10 À3 ) (Supplemental Table 1 and Supplemental Fig. 1 ). Thus, autoimmune disease associated noncoding SNPs in the PTPN2 locus are linked to differential expression levels of the lncRNAs LINC01882 and RP11-973H7.1 in healthy individuals.
Relationship between SNPs in the PTPN2 locus, methylation profiles and lncRNA expression in RA patients
Following the identified relationship between SNPs in the PTPN2 locus and DNA methylation at four CpG sites 7.5 kb downstream of PTPN2 in healthy individuals, we tested this relationship in whole blood genomic DNA from 354 anti-citrullinated protein antibody (ACPA)-positive RA patients. Similarly, most of the 37 SNPs are methQTLs for the four CpG sites (cg23598886, cg23544223, cg24737193, and cg09945482) in RA patients (Fig. 3A) . Carriers of the minor allele (G allele) of rs1893217 showed lower methylation levels at cg23598886 (P ¼ 1.78 Â 10 À37 ), cg23544223 (P ¼ 6.51 Â 10 À37 ), cg24737193 (P ¼ 1.83 Â 10 À26 ), and cg09945482
(P ¼ 5.28 Â 10 À22 )). In addition, we observed an additive interaction between the SNPs rs1893217, rs657555, and rs2847297 in the PTPN2 locus and the major genetic risk factor for RA, HLA-DRB1 shared epitope (SE) alleles (Supplemental Fig. 2 ). Although the methQTLs were only significant in SE positive patients, we observed a trend in SE negative patients (Supplemental Fig. 3) . Thus, autoimmune disease associated non-coding SNPs in the PTPN2 locus are linked to differential methylation at four CpG sites in RA patients. Next, we tested the association between SNPs in the PTPN2 locus and expression levels of PTPN2, LINC01882, and RP11-973H7.1 in PBMCs of RA patients from the COMBINE study. In RA patients, the SNPs are only weakly associated with the expression of PTPN2 (Fig. 3B) , but are strongly associated with the expression of LINC01882 (Fig. 3C) and RP11-973H7.1 (Fig. 3D) . The SNPs in high LD with rs12971201 are associated with the expression of LINC01882 (P ¼ 2.08 Â 10 À7 ) and RP11-973H7.1 (P ¼ 3.17 Â 10
À7
) (Supplemental Table 2 and Supplemental Fig. 4 ). The SNP rs1893217 is weakly associated with the expression of RP11-973H7.1 (P ¼ 6.21 Â 10 À3 )
and not associated with LINC01882. Also following stratification by HLA-DRB1 SE alleles the association between rs12971201 and LINC01882 (P SE-positive ¼ 3.91 Â 10 À4 , P SE-negative ¼ 2.16 Â 10 À4 ) or RP11-973H7.1 expression (P SE-positive ¼ 3.00 Â 10 À4 , P SE-negative ¼ 2.26 Â 10 À4 ) was evident (Supplemental Fig. 5 ). These results
show that autoimmune disease associated non-coding SNPs in the PTPN2 locus are also associated to differential expression levels of the lncRNAs LINC01882 and RP11-973H7.1 in RA patients.
Expression of LINC01882 and RP11-973H7.1 in T cells
As previous analyses of lncRNAs in various tissues have indicated that lncRNA expression is more cell-type specific than mRNA expression [37] , we determined the expression of LINC01882 and Table 2 and Supplemental Fig. 4 .
RP11-973H7.1 in CD4
þ and CD8 þ T cells, CD14 þ monocytes, and CD19 þ B cells from healthy individuals using RNAseq. We could only detect LINC01882 expression in CD4 þ and CD8 þ T cells (Fig. 4A ). Our data also shows that RP11-973H7.1 is mainly expressed in CD4 þ and CD8 þ T cells, with only low levels of this lncRNA in CD14 þ monocytes and CD19 þ B cells (Fig. 4B ). In addition, interrogating available H3K27ac ChIP-seq data from the Roadmap Epigenomics project for different tissue and cell types, we found a H3K27ac peak just upstream of the lncRNA RP11-973H7.1 in T cells (Fig. 4C ). This H3K27ac peak was not found in monocytes and B cells. This data demonstrates that the lncRNAs LINC01882 and RP11-973H7.1 are mainly expressed in T cells.
To investigate the expression of LINC01882 in CD4 þ T cells in more detail, we measured the expression of this lncRNA in naïve CD4 þ T cells and in CD3/CD28 activated naive CD4 þ T cells using RNAseq. We detected that the expression of LINC01882 is decreased after activation (P ¼ 1.01 Â 10 À3 ) (Fig. 4D) . The expression of RP11-973H7.1 could not be detected in this data set due to the preparation of the sequencing library using poly(A) enrichment.
Knockdown of LINC01882 in Jurkat T cells
To analyze the role of LINC01882 in T cells, we used a combination of a GapmeR and a dsiRNA, targeting the second exon of LINC01882, to suppress the expression of LINC01882 in Jurkat T cells. The expression of LINC01882 is analyzed in Jurkat T cells and it is several times lower than PTPN2 expression (Supplemental Fig. 6 ), similarly as in primary T cells. The combination of a GapmeR and a dsiRNA resulted in about 80% reduction of LINC01882 after 24 h and about 75% reduction of LINC01882 after 48 h in comparison with the combination of a control GapmeR and dsiRNA (Fig. 5A ). Assuming that a potential function of lncRNAs could be regulating the expression of neighboring protein-coding genes in the genome, we tested the expression of PTPN2 after LINC01882 knockdown. However, within our experimental setup, our data demonstrated that the knockdown of LINC01882 did not affect the expression levels of the closest gene, PTPN2 (Fig. 5B) .
As PTPN2 expression levels were not influenced by LINC01882, we evaluated the global genomic effects of LINC01882 knockdown in Jurkat T cells using RNAseq. Our data shows that 6 genes were upregulated and 6 genes were downregulated by LINC01882 knockdown (FDR < 0.05) (Fig. 5C and Table 1 ). The most upregulated gene upon LINC01882 knockdown is BZRAP1 (Table 1) , but no function for BZRAP1 has been reported for blood cells. The knockdown of LINC01882 also downregulated the expression of MAP2K4 and ZEB1 (Table 1) , where MAP2K4 is a component of the kinase cascade that mediates cellular responses to cytokine signals and stress and ZEB1 encodes a transcription factor that represses IL2 expression in T cells when it cooperates with the co-repressor Cterminal-binding protein (CtBP) 2 [38] . Together, these results suggest that LINC01882 is involved in T cell activation.
Discussion
Several non-coding SNPs in the PTPN2 locus have been associated to the autoimmune diseases T1D, JIA, IBD, and RA [5e8], however, the functional consequences of these variations in disease pathogenesis remain unclear. The main finding in our study focusing on RA is that autoimmune disease associated genetic variations in the PTPN2 locus are involved in regulation of the lncRNAs LINC01882 (also known as LOC100996324 and RP11-973H7.4) and RP11-973H7.1 that are mainly expressed in T cells. Silencing of LINC01882 in a T cell line affected the expression of several genes, including the transcription factor ZEB1 and kinase MAP2K4, and suggests the involvement of this lncRNA in T cell activation.
Previous GWA studies have identified PTPN2 as a candidate gene for autoimmune diseases [5e8,10e17]. PTPN2 encodes PTPN2, also known as T cell PTP, and has been shown to act on several phosphorylated proteins, such as Janus-activated kinases (JAKs) and signal transducers and activators of transcription (STATs), to regulate cytokine signaling [9, 39] . Although these studies show that PTPN2 is an important factor in autoimmunity, it is not clear how the autoimmune disease associated genetic variations may influence PTPN2. PTPN2 knockout mice die 3e5 weeks after birth from severe inflammatory disease, marked by increased expression of the pro-inflammatory cytokines tumor necrosis factor (TNF) and interferon-gamma (IFN-y) [40] . It has been shown that PTPN2 is a critical negative regulator of T cell receptor (TCR) signaling by dephosphorylating the Src family kinases Lck and Fyn to prevent autoimmunity [41] . PTPN2 restrains CD8
þ T cell differentiation after antigen cross-presentation [42] . More recently, it has been shown that PTPN2 deficiency drives germinal center B cell differentiation and the generation of potentially autoreactive antibodies [43] .
A study in patients with Crohn's disease has identified that the SNP rs2542151 is associated with lower protein levels of PTPN2 in colonic lamina propria fibroblasts and causes aberrant autophagosome formation in human intestinal cells [44] . Another study identified that healthy individuals carrying the T1D-associated rs1893217 risk allele had decreased RNA levels of PTPN2 in CD4 þ CD45RO þ T cells [45] . However, our results, from whole blood samples or PBMCs of healthy individuals and RA patients, do not suggest that these SNPs or other autoimmune disease-associated SNPs are correlated with the expression of PTPN2. As eQTLs are known to be cell-type specific [46] , we might have missed the previously mentioned association of rs1893217 with PTPN2 in our expression data sets. On the other hand, our data clearly shows that the SNPs in the PTPN2 locus are associated with the expression of LINC01882 and RP11-973H7.1. We found that the SNPs in high LD with rs12971201 have the strongest associations with LINC01882 Volcano plot displaying the genes significantly upregulated (red) and downregulated (blue) after LINC01882 knockdown, assessed by RNAseq. This data is from two independent knockdown experiments where the two time points (24 and 48 h) were combined. P-values were estimated by the Wald test in DESeq2 adjusted for experiments and time points. Quantitative real time PCR data (AeB) are from three independent knockdown experiments and one qPCR experiment where each sample was run in triplicates. HPRT and SFRS9 were used to normalize gene expression levels. Bars represent mean ± SEM. Abbreviations: C: control, KD: knockdown of LINC01882.
and RP11-973H7.1 expression, whereas the SNPs in high LD with rs1893217 are strongly associated with methylation levels in the CpG island. Although the eQTLs and methQTLs are inversely correlated, in line with the traditional view that decreased CpG island methylation is associated with increased expression of transcripts nearby [47] , it is not clear whether the change in expression of LINC01882 or RP11-973H7.1 is a direct consequence of DNA methylation changes or that it all depends on other factors, including environmental effects. In addition, the promoter region of PTPN2 where the SNPs rs4797709 (in high LD with rs12971201) and rs2292759 are located, physically interacts with LINC01882 in different cell types, including CD4 þ and CD8 þ T cells [48] .
The methQTLs and eQTLs were detected in both healthy individuals and RA patients. The SNPs in high LD with rs1893217 are strongly associated with methylation levels of the four CpG sites regardless disease status. The SNP that is most significantly associated with the expression of LINC01882 in healthy individuals is rs11875687. However, in RA patients, the SNPs in high LD with rs12971201 are most significantly associated with the expression of LINC01882. The SNPs in high LD with rs12971201 are also most significantly associated with the expression of RP11-973H7.1 in both healthy individuals and RA patients. These findings suggest a difference in regulation of lncRNA expression in this locus in PBMCs from healthy individuals and RA patients through different methQTLs and provide insights into the underlying biology of the PTPN2 locus.
RA patients can be classified into subgroups according to the presence of circulating autoantibodies. One major subgroup is ACPA-positive RA, which represents a group of RA patients with higher disease severity [49] . HLA-DRB1 SE alleles are cumulatively the highest known genetic risk factor for seropositive RA. We, and others, have previously demonstrated that some of the autoimmune disease-related SNPs are in interaction with HLA-DRB1 SE alleles in ACPA-positive RA [50e52]. This indicates a disease mechanism for ACPA-positive RA that requires co-occurrence of HLA-DRB1 SE alleles and the risk allele of certain RA associated SNPs in the PTPN2 locus. Although the methQTLs were only significant in HLA-DRB1 SE positive RA patients, there is a trend in the smaller group of SE negative RA patients (Supplemental Fig. 3 ).
More specific biological interpretation of the role of autoimmune disease-related non-coding SNPs in the PTPN2 locus remains ambiguous. To further explore the regulatory role of these SNPs, we used the online data sources HaploReg [35] and RegulomeDB [36] . These sources do not provide evidence that SNPs in high LD with rs1893217 are regulatory. On the other hand, the SNPs rs2852151 and rs3826557, in high LD with rs12971201, are more likely to be regulatory. These SNPs are located in binding sites for transcription factors and DNA-damage repair proteins, such as RAD21, CTCF, STAT3, FOS, and STAT1 [35, 36] . Differential binding of these proteins to the risk allele of SNPs in the PTPN2 locus might influence the expression of LINC01882 and RP11-973H7.1. However, these lncRNAs are not differentially expressed between healthy individuals and RA patients, in whole blood samples and PBMCs. This can reflect that modulation of the pathways related to RA development takes place long before development of clinical symptoms and changes of lncRNA levels could be compensated in chronic disease. For example, it is well-established that individuals with ACPA-positive RA develop signs of autoimmunity many years before disease onset [53] . Alternatively, it could be explained by activation of cells during separation of PBMCs. We detected that the expression of LINC01882 and RP11-973H7.1 were more abundant in T cells, therefore it would be interesting to measure the expression of these lncRNAs in specific T cell populations and preferably at earlier stages of disease development.
The methQTLs and eQTLs suggest that the lncRNAs LINC01882 and RP11-973H7.1 might be involved in different autoimmune diseases, including RA. LncRNAs are RNA transcripts traditionally defined as over 200 nucleotides in length, which may participate in many cellular regulatory processes. Over the past decade, over 50,000 lncRNAs have been identified in humans [54, 55] . Recently, it has become clear that lncRNAs are important regulators of gene expression and are implicated in human diseases [56] . In addition, many lncRNAs have been found to be critical regulators of gene expression in the immune system [57] . However, the function of LINC01882 and RP11-973H7.1 in RA have not been investigated.
To identify potential functions of LINC01882, we silenced the expression of this lncRNA in Jurkat T cells using a combination of an antisense oligonucleotide and RNA interference. The modest change in expression levels of 12 genes might be due to the low expression of LINC01882 in T cells. The most upregulated gene is BZRAP1. It has been shown that BZRAP1 interacts with peripheral benzodiazepine receptor, Rab-3 interacting molecules, and voltagegated Ca 2þ -channels in brain tissue [58] . However, the function of BZRAP1 in immune cells is not known. The knockdown of LINC01882 also downregulated the expression of ZEB1. ZEB1 encodes a zinc finger and homeodomain transcription factor that represses IL2 expression in T cells when it cooperates with CtBP2 and binds to the promoter of IL2 [38] . It is not predicted that LINC01882 binds directly to ZEB1. More recently, it has been shown that the microRNA miR-200a-3p negatively regulates the recruitment of ZEB1 and CtBP2 and promotes IL-2 production in T cells [59] . There is prediction data that LINC01882 could interact with miR-200a-3p [60] . We hypothesize that LINC01882 regulates the expression of ZEB1 by regulating the expression of miR-200a-3p. In addition, it is predicted that miR-200a-3p can interact with KLF12 and MAP2K4, which are both affected by the silencing of LINC01882. These results suggest that LINC01882 is potentially involved in the regulation of IL-2 expression (Fig. 6 ). IL-2 influences various lymphocyte subsets during differentiation, immune responses, and homeostasis. One of the crucial roles of IL-2 is the maintenance of regulatory T cells. These cells play an important role in controlling autoimmune responses and changes in the number of regulatory T cells could lead to the development of RA and other autoimmune diseases. In addition, clinical trials with low-dose IL-2 can control autoimmune diseases [61] . We also demonstrated earlier a genegene interaction between MAP2K4 and HLA-DRB1 SE alleles in development of ACPA-positive RA [51] .
It was previously noticed that association hits in intergenic regions and even inside the gene do not necessarily correspond to the function of the closest gene. The CLEC16A locus is one of the examples. Variations in this locus do not influence the expression of CLEC16A, but a distinct influence on the expression of DEXI, separated by a loop of >150 kb, was found [1, 62] . Our findings present similar example of distant effects for the SNPs found in GWA studies.
Conclusions
Our study indicates the involvement of LINC01882 in autoimmune diseases where PTPN2 SNPs are known to be associated. Further detailed studies would be necessary to assess the exact role of LINC01882 in T cells in relation to disease development.
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